Trial · NCT02927314
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
NCT02927314, Phase 2, Completed, Can-Fite BioPharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease. Trials, record NCT02927314. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02927314
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
- NCT number
- NCT02927314
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 60 participants, actual
- Lead sponsor
- Can-Fite BioPharma
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- CF102, Placebo
- First posted
- 2016-10-07
- Last updated
- 2020-03-17
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levels | 12 weeks | Mean percent change in serum alanine aminotransferase (ALT) levels |
| Primary | Efficacy of CF102 as determined by change in magnetic resonance imaging-determined hepatic steatosis | 12 weeks | Percent change from Baseline in hepatic steatosis measured by magnetic resonance imaging-determined proton-density fat-fraction (MRI-PDFF) |
| Secondary | Body weight in subjects with NAFLD | 12 weeks | Change from baseline in body weight (kg) |
| Secondary | Waist circumference in subjects with NAFLD | 12 weeks | Change from baseline in waist circumference (cm) |
| Secondary | HDL cholesterol levels in subjects with NAFLD | 12 weeks | Change from baseline in serum triglyceride and HDL cholesterol levels (mg/dL) |
| Secondary | Normalization of serum ALT levels in subjects with NAFLD | 12 weeks | Proportion of all subjects whose serum ALT level normalizes |
| Secondary | Serum aspartate aminotransaminase (AST) levels in subjects with NAFLD | 12 weeks | Change from baseline in serum AST levels |
| Secondary | Hemoglobin A1c levels and degree of insulin resistance | 12 weeks | Change from baseline in Homeostasis Model Assessment (HOMA) |
| Secondary | Pharmacokinetics (PK) of CF102 in this population | 12 weeks | PK of CF102 will be assessed through steady state trough drug level |
| Secondary | Peripheral blood expression of the A3 adenosine receptor (A3AR). | 12 weeks | Change from baseline in A3 adenosine receptor (A3AR) expression level |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02927314
GET https://conductscience.org/api/trials/v1/NCT02927314/registered